164 related articles for article (PubMed ID: 26001631)
1. Safety of biologic and nonbiologic disease-modifying antirheumatic drug therapy in veterans with rheumatoid arthritis and hepatitis B virus infection: a retrospective cohort study.
Burton MJ; Curtis JR; Yang S; Chen L; Singh JA; Mikuls TR; Winthrop KL; Baddley JW
Arthritis Res Ther; 2015 May; 17(1):136. PubMed ID: 26001631
[TBL] [Abstract][Full Text] [Related]
2. Safety of Biologic and Nonbiologic Disease-modifying Antirheumatic Drug Therapy in Veterans with Rheumatoid Arthritis and Hepatitis C Virus Infection.
Burton MJ; Curtis JR; Yang S; Chen L; Singh JA; Mikuls TR; Winthrop KL; Baddley JW
J Rheumatol; 2017 May; 44(5):565-570. PubMed ID: 28250142
[TBL] [Abstract][Full Text] [Related]
3. Examining Time to Initiation of Biologic Disease-modifying Antirheumatic Drugs and Medication Adherence and Persistence Among Texas Medicaid Recipients With Rheumatoid Arthritis.
Kim G; Barner JC; Rascati K; Richards K
Clin Ther; 2016 Mar; 38(3):646-54. PubMed ID: 26899313
[TBL] [Abstract][Full Text] [Related]
4. Factors associated with the initiation of biologic disease-modifying antirheumatic drugs in Texas Medicaid patients with rheumatoid arthritis.
Kim G; Barner JC; Rascati K; Richards K
J Manag Care Spec Pharm; 2015 May; 21(5):401-7. PubMed ID: 25943001
[TBL] [Abstract][Full Text] [Related]
5. Risk of venous thromboembolism in patients with rheumatoid arthritis: initiating disease-modifying antirheumatic drugs.
Kim SC; Solomon DH; Liu J; Franklin JM; Glynn RJ; Schneeweiss S
Am J Med; 2015 May; 128(5):539.e7-17. PubMed ID: 25534420
[TBL] [Abstract][Full Text] [Related]
6. Safety of disease modifying anti-rheumatic agents in rheumatoid arthritis patients with chronic viral hepatitis.
Mok MY; Ng WL; Yuen MF; Wong RW; Lau CS
Clin Exp Rheumatol; 2000; 18(3):363-8. PubMed ID: 10895374
[TBL] [Abstract][Full Text] [Related]
7. Reactivation of hepatitis B virus in rheumatoid arthritis patients treated with biological disease-modifying antirheumatic drugs.
Nakamura J; Nagashima T; Nagatani K; Yoshio T; Iwamoto M; Minota S
Int J Rheum Dis; 2016 May; 19(5):470-5. PubMed ID: 24698305
[TBL] [Abstract][Full Text] [Related]
8. Association between disease-modifying antirheumatic drugs and diabetes risk in patients with rheumatoid arthritis and psoriasis.
Solomon DH; Massarotti E; Garg R; Liu J; Canning C; Schneeweiss S
JAMA; 2011 Jun; 305(24):2525-31. PubMed ID: 21693740
[TBL] [Abstract][Full Text] [Related]
9. Treatment Patterns with Disease-Modifying Antirheumatic Drugs in U.S. Veterans with Newly Diagnosed Rheumatoid Arthritis, Psoriatic Arthritis, or Ankylosing Spondylitis.
Walsh JA; Pei S; Penmetsa GK; Sauer BC; Patil V; Walker JH; Clewell J; Douglas KM; Clegg DO; Cannon GW; Halwani A
J Manag Care Spec Pharm; 2019 Nov; 25(11):1218-1228. PubMed ID: 31663467
[TBL] [Abstract][Full Text] [Related]
10. Commensurate incidence and outcomes of liver enzyme elevation between anti-tumor necrosis factor users with or without prior hepatitis B virus infections.
Chiu YM; Lai MS; Chan KA
PLoS One; 2018; 13(4):e0196210. PubMed ID: 29694398
[TBL] [Abstract][Full Text] [Related]
11. Risk of hepatotoxicity with add-on leflunomide in rheumatoid arthritis patients.
Gupta R; Bhatia J; Gupta SK
Arzneimittelforschung; 2011; 61(5):312-6. PubMed ID: 21755815
[TBL] [Abstract][Full Text] [Related]
12. Practice Pattern of Hepatitis B Testing in Rheumatoid Arthritis Patients: A Cross-National Comparison Between the US and Taiwan.
Lin TC; Hashemi N; Kim SC; Yang YK; Yoshida K; Tedeschi S; Desai R; Solomon DH
Arthritis Care Res (Hoboken); 2018 Jan; 70(1):30-38. PubMed ID: 28320050
[TBL] [Abstract][Full Text] [Related]
13. Biologic Disease-Modifying Antirheumatic Drugs and Risk of High-Grade Cervical Dysplasia and Cervical Cancer in Rheumatoid Arthritis: A Cohort Study.
Kim SC; Schneeweiss S; Liu J; Karlson EW; Katz JN; Feldman S; Solomon DH
Arthritis Rheumatol; 2016 Sep; 68(9):2106-13. PubMed ID: 27015113
[TBL] [Abstract][Full Text] [Related]
14. Safety of infliximab therapy in rheumatoid arthritis patients with previous exposure to hepatitis B virus.
Zhang X; Zhang F; Wu D; Bao C; Zhu P; Zhang X; Huang C; He D; Tao Y; Fang Y; Gu J; Wu H; Sun L; Yang X; Huang F; Xu H; Zhao D; Zhang M; Zheng Y; Li Z
Int J Rheum Dis; 2013 Aug; 16(4):408-12. PubMed ID: 23992260
[TBL] [Abstract][Full Text] [Related]
15. Risk of Subsequent Infection Among Patients Receiving Tumor Necrosis Factor Inhibitors and Other Disease-Modifying Antirheumatic Drugs.
Accortt NA; Bonafede MM; Collier DH; Iles J; Curtis JR
Arthritis Rheumatol; 2016 Jan; 68(1):67-76. PubMed ID: 26359948
[TBL] [Abstract][Full Text] [Related]
16. Kinetics of viral loads and risk of hepatitis B virus reactivation in hepatitis B core antibody-positive rheumatoid arthritis patients undergoing anti-tumour necrosis factor alpha therapy.
Lan JL; Chen YM; Hsieh TY; Chen YH; Hsieh CW; Chen DY; Yang SS
Ann Rheum Dis; 2011 Oct; 70(10):1719-25. PubMed ID: 21719446
[TBL] [Abstract][Full Text] [Related]
17. [Methotrexate, liver and rheumatoid arthritis in tropical areas].
Diouf ML; Diallo S; Mbengue M; Moreira-Diop T
Sante; 2001; 11(3):195-200. PubMed ID: 11641084
[TBL] [Abstract][Full Text] [Related]
18. Use of nonbiologic disease-modifying antirheumatic drugs and risk of infection in patients with rheumatoid arthritis.
Lacaille D; Guh DP; Abrahamowicz M; Anis AH; Esdaile JM
Arthritis Rheum; 2008 Aug; 59(8):1074-81. PubMed ID: 18668604
[TBL] [Abstract][Full Text] [Related]
19. Safety of rituximab in combination with other biologic disease-modifying antirheumatic drugs in rheumatoid arthritis: an open-label study.
Rigby WF; Mease PJ; Olech E; Ashby M; Tole S
J Rheumatol; 2013 May; 40(5):599-604. PubMed ID: 23547218
[TBL] [Abstract][Full Text] [Related]
20. Treatment patterns in psoriatic arthritis patients newly initiated on oral nonbiologic or biologic disease-modifying antirheumatic drugs.
Zhang HF; Gauthier G; Hiscock R; Curtis JR
Arthritis Res Ther; 2014 Aug; 16(4):420. PubMed ID: 25146329
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
